远程医疗生活方式干预项目TeLiPro在晚期2型糖尿病中的疗效:一项随机对照试验
本研究在德国纳入HbA1c≥7.5%且BMI≥27 kg/m2、使用≥2种降糖药的2型糖尿病患者,随机分为TeLiPro远程医疗教练组(n=102)与常规护理对照组(n=100)。12周后TeLiPro组HbA1c降幅显著大于对照组(-1.1±1.2% vs -0.2±0.8%,P<0.0001),完全校正模型估计治疗差异为0.8%(95%CI 1.1;0.5),并维持至26周和52周随访。
要点
- TeLiPro组12周HbA1c降幅-1.1±1.2%,对照组-0.2±0.8%,差异显著(P<0.0001)。
- 完全校正模型估计治疗差异0.8%(95%CI 1.1;0.5),第26周0.6%(95%CI 1.0;0.3)、第52周0.6%(95%CI 0.9;0.2)。
- 体重、BMI、收缩压、10年心血管病风险、降糖药、生活质量与进食行为等次要结局均显著改善(P<0.01)。
核心结论
- 在晚期2型糖尿病中,TeLiPro可改善血糖控制,并可能为避免药物强化提供新选择。
研究设计与样本
- 单盲、活性对照、干预研究,在德国招募2型糖尿病且HbA1c≥7.5%(58.5 mmol/mol)、BMI≥27 kg/m2、使用≥2种降糖药的患者。
- 采用电子生成的随机列表和密封信封按1:1随机分为两组平行组,数据分派后设盲分析。
- 对照组n=100接受体重秤和计步器并维持常规护理;TeLiPro组n=102额外接受12周远程医疗教练,包括医学-心理动机、配方饮食和自我血糖监测。
- 主要终点为12周后HbA1c降幅的估计治疗差异,分析所有可获得的每例患者数值(n=202),并在26周和52周随访时分析。
主要发现
- TeLiPro组HbA1c降幅(均值±SD)-1.1±1.2% vs 对照组-0.2±0.8%,P<0.0001。
- 完全校正模型估计治疗差异为0.8%(95%CI 1.1;0.5),P<0.0001。
- 随访期间TeLiPro的治疗优效性维持:第26周0.6%(95%CI 1.0;0.3),P=0.0001;第52周0.6%(95%CI 0.9;0.2),P<0.001。
- 次要结局:体重TeLiPro -6.2±4.6 kg vs 对照组-1.0±3.4 kg;BMI -2.1±1.5 kg/m2 vs -0.3±1.1 kg/m2;收缩压-5.7±15.3 mmHg vs -1.6±13.8 mmHg;10年心血管病风险、降糖药、生活质量与进食行为均P<0.01,效应长期维持。
- 未报告不良事件。
临床怎么用
- 原文结论指出,在晚期2型糖尿病中TeLiPro可改善血糖控制,并可能为避免药物强化提供新选择(作者认为)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lifestyle interventions are the foundation of treatment in newly diagnosed type 2 diabetes. However, their therapeutic potential in advanced disease stages is unknown. We evaluated the efficacy of the Telemedical Lifestyle intervention Program (TeLiPro) in improving metabolic control in advanced-stage type 2 diabetes. RESEARCH DESIGN AND METHODS: In this single-blind, active comparator, intervention study, patients with type 2 diabetes (with glycated hemoglobin [HbA1c] ≥7.5% [58.5 mmol/mol]), and BMI ≥27 kg/m2 and on ≥2 antidiabetes medications) were recruited in Germany and randomized 1:1 using an electronically generated random list and sealed envelopes into two parallel groups. The data analyst was blinded after assignment. The control group (n = 100) got weighing scales and step counters and remained in routine care. The TeLiPro group (n = 102) additionally received telemedical coaching including medical-mental motivation, a formula diet, and self-monitored blood glucose for 12 weeks. The primary end point was the estimated treatment difference in HbA1c reduction after 12 weeks. All available values per patient (n = 202) were analyzed. Analyses were also performed at 26 and 52 weeks of follow-up. RESULTS: HbA1c reduction was significantly higher in the TeLiPro group (mean ± SD -1.1 ± 1.2% vs. -0.2 ± 0.8%; P < 0.0001). The estimated treatment difference in the fully adjusted model was 0.8% (95% CI 1.1; 0.5) (P < 0.0001). Treatment superiority of TeLiPro was maintained during follow-up (week 26: 0.6% [95% CI 1.0; 0.3], P = 0.0001; week 52: 0.6% [0.9; 0.2], P < 0.001). The same applies for secondary outcomes: weight (TeLiPro -6.2 ± 4.6 kg vs. control -1.0 ± 3.4 kg), BMI (-2.1 ± 1.5 kg/m2 vs. -0.3 ± 1.1 kg/m2), systolic blood pressure (-5.7 ± 15.3 mmHg vs. -1.6 ± 13.8 mmHg), 10-year cardiovascular disease risk, antidiabetes medication, and quality of life and eating behavior (P < 0.01 for all). The effects were maintained long-term. No adverse events were reported. CONCLUSIONS: In advanced-stage type 2 diabetes, TeLiPro can improve glycemic control and may offer new options to avoid pharmacological intensification.
引用
- Kempf K, Altpeter B, Berger J, et al. Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2017. PMID: 28500214. doi:10.2337/dc17-0303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。